Details of the Drug Therapeutic Target (DTT)

General Information of Drug Therapeutic Target (DTT) (ID: TTQ29KF)

DTT Name	Voltage-gated potassium channel Kv7 (KCNQ)
Synonyms	Voltage-gated potassium channel subunit Kv7; Potassium voltage-gated channel subfamily KQT; Kv7; KVLQT; KQT-like; IKs producing slow voltage-gated potassium channel subunit alpha KvLQT; IKs producing slow voltage-gated potassium channel alpha subunit KvLQT
Gene Name	KCNQ
DTT Type	Clinical trial target	[1]
BioChemical Class	Voltage-gated ion channel
UniProt ID	NOUNIPROTAC
TTD ID	T86192
KEGG Pathway	Adrenergic signaling in cardiomyocytes (hsa04261 ) Cholinergic synapse (hsa04725 ) Gastric acid secretion (hsa04971 ) Pancreatic secretion (hsa04972 ) Protein digestion and absorption (hsa04974 ) Vibrio cholerae infection (hsa05110 )

Molecular Interaction Atlas (MIA) of This DTT

Molecular Interaction Atlas (MIA)

Jump to Detail Molecular Interaction Atlas of This DTT

1 Approved Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
Retigabine	DMGNYIH	Behcet disease	4A62	Approved	[2]
------------------------------------------------------------------------------------

2 Clinical Trial Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
CNSB-001	DM2PEU5	Neuropathic pain	8E43.0	Phase 2	[1]
Flupirtine	DMPBV9D	Cancer related pain	MG30	Phase 2	[3]
------------------------------------------------------------------------------------

1 Discontinued Drug(s) Targeting This DTT

Drug Name	Drug ID	Indication	ICD 11	Highest Status	REF
DMP-543	DMCNEOZ	Parkinson disease	8A00.0	Discontinued in Phase 2	[4]
------------------------------------------------------------------------------------

Molecular Expression Atlas (MEA) of This DTT

Molecular Expression Atlas (MEA)

Jump to Detail Molecular Expression Atlas of This DTT

Disease Name	ICD 11	Studied Tissue	p-value	Fold-Change	Z-score
Parkinson's disease	8A00.0	Substantia nigra tissue	6.24E-01	0.11	0.85
------------------------------------------------------------------------------------

References

1	The Kv7 potassium channel activator flupirtine affects clinical excitability parameters of myelinated axons in isolated rat sural nerve. J Peripher Nerv Syst. 2010 Mar;15(1):63-72.
2	Antibodies and venom peptides: new modalities for ion channels. Nat Rev Drug Discov. 2019 May;18(5):339-357.
3	Treatment with the Kv7 potassium channel activator flupirtine is beneficial in two independent mouse models of pulmonary hypertension. Br J Pharmacol. 2009 August; 157(7): 1241-1249.
4	KV7 channels regulate muscle tone and nonadrenergic noncholinergic relaxation of the rat gastric fundus.Pharmacol Res.2011 Oct;64(4):397-409.